MedTrace Logo

Effects of Vitamin B3 in Patients With Ataxia Telangiectasia

NCT03962114 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2022-07-25

No results posted yet for this study

Summary

This clinical trial investigates the effects of nicotinamide riboside (vitamin B3) on the disease course of patients with ataxia telangiectasia.

Patients will be treated during four consecutive months with nicotinamide riboside (25mg/kg/day), followed by a washout period of two months.

Main study parameters/endpoints: Ataxia, dysarthria, quality of life, laboratory parameters.

Conditions

  • Ataxia Telangiectasia
  • ATM Gene Mutation

Interventions

DIETARY_SUPPLEMENT

Vitamin B3

capsules with niagen

Sponsors & Collaborators

  • A-T Children's Project

    collaborator OTHER

  • Twan foundation (https://twanfoundation.nl)

    collaborator UNKNOWN

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-18
Primary Completion
2019-12-01
Completion
2020-03-01

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03962114 on ClinicalTrials.gov